Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil

International Journal of Clinical Pharmacology and Therapeutics

Volumn 42, Issue 9, 2004, Pages 512-518

  Reyderman, Larisa ^a   Kosoglou, T ^a   Statkevich, P ^a   Pember, L ^a   Boutros, T ^a   Maxwell, S E ^a   Affrime, M ^a   Batra, V ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Drug interaction; Ezetimibe; Gemfibrozil; Multiple dose; Pharmacokinetic

Indexed keywords

DRUG METABOLITE; EZETIMIBE; GEMFIBROZIL;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG CONJUGATION; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MULTIPLE DRUG DOSE; MYALGIA; NORMAL HUMAN; OPEN STUDY; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; STEADY STATE; VOLUNTEER;

EID: 4544247030     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP42512     Document Type: Article

References (23)

1. Bays HE, Moore PB, Dreholb MA et al 2001 Effectiveness and tolerability of ezetimibe in subjects with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 23: 1209-1230
2. Bloomfield Rubins H, Davenport J, Babikian V et al 2001 Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 103: 2828-2833
3. Ezzet F, Krishna G, Wexler D et al 2001 A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther 23: 871-885
4. Fruchart JC, Staels B, Duriez P 2001 The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 3: 83-92
5. Gibaldi M, Perrier D 1980 Noncompartmental analysis based on statistical moment theory. In: Swarbrick J. (eds) Pharmacokinetics (2nd ed). Marcel Dekker, New York, 409-417
6. Hermening A, Gräfe A-K, Baktir G et al 2000 Gemfibrozil and its oxidative metabolites: quantification of aglycones, acyl glucuronides, and covalent adducts in samples from preclinical and clinical kinetic studies. J Chromatogr B 741: 129-144
7. Knopp RH, Bays H, Manion CV et al 2001a Effect of ezetimibe on serum concentrations of lipid-soluble vitamins. Atherosclerosis 2 (Suppl): 90
8. Knopp RH, Gitter H, Truitt T et al 2001b Ezetimibe reduces low-density lipoprotein cholesterol: results of a Phase III, randomized, double-blind, placebo-controlled trial. Atherosclerosis 2 (Suppl): 38
9. Kosoglou T, Meyer I, Veltri EP et al 2002 Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 54: 309-319
10. Miller DB, Spence JD 1998 Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 34: 155-162
11. Patrick JE, Kosoglou T, Stauber KE et al 2002 Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos 30: 430-437
12. Prueksaritanont T, Zhao JJ, Ma B et al 2002 Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 301: 1042-1051
13. Shepherd J 1995 Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J 16: 5-13
14. Spencer CM, Barradell LB 1996 Gemfibrozil: a reappraisal of its pharmacological properties and place in the management of dyslipidaemia. Drugs 51: 982-1018
15. Stein E 2001 Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur Heart J 3 (Suppl E): E11-E16
16. Sudhop T, von Bergmann K 2002 Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. Drugs 62: 2333-2347
17. Sudhop T, Lütjohann D, Kodal A et al 2002 Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106: 1943-1948
18. van Heek M, Farley C, Compton DS et al 2000 Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 129: 1748-1754
19. van Heek M, France CF, Compton DS et al 1997 In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 283: 157-163
20. Watts GF, Dimmitt SB 1999 Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol 10: 561-574
21. Witztum JL 1996 Drugs used in the treatment of hyperdyslipidemias. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds) Goodman and Gilman's The Pharmacological Basis of Therapeutics (9th ed). McGraw-Hill, New York, pp 875-897
22. Zhu Y, Statkevich P, Kosoglou T et al 1999 The effect of gender on the pharmacokinetics of SCH 58235, a cholesterol absorption inhibitor. Am Assoc Pharm Sci (AAPS) Suppl 1: S-24
23. Zhu Y, Statkevich P, Kosoglou T et al 2000 Effect of ezetimibe (SCH 58235) on the activity of drug metabolizing enzymes in vivo. Clin Pharmacol Ther 67:152